New migraine drug approved for children while puberty blockers remain restricted
A brand-new migraine medication has been cleared for trials in children as young as six, raising questions about why established puberty blockers with decades of safety data face ongoing restrictions.18 March 2026
Regulatory decisions about which treatments can be tested or prescribed to children should be guided by robust evidence and consistent principles. Yet we are seeing a striking inconsistency in how different medications are evaluated and approved for paediatric use.
A newly developed migraine drug has just received the green light for clinical trials in children as young as six years old. This is encouraging news for young people with migraine, and the rigorous trial process exists for good reason. At the same time, puberty blockers—which have been used safely in clinical practice for decades, with extensive safety data across multiple conditions—remain subject to significant restrictions and barriers to access.
This contradiction deserves scrutiny. Read the full article to explore what this reveals about how we assess risk, weigh evidence, and make decisions that affect young people's healthcare.